Background/aims: Quantitative data regarding the impact of neovascular age-related macular degeneration (NV-AMD) on individuals and society is a prerequisite for rational decision-making processes when evaluating alternative treatments for the disease.
Methods: Seventy-five bilateral NV-AMD (patients) and 91 elderly non-AMD (controls) subjects forming the United Kingdom cohort of an international cross-sectional, observational study were independently analysed. Subjects completed a telephone survey including the National Eye Institute Visual Function Questionnaire (NEI-VFQ-25), the EuroQol (EQ-5D), the Hospital Anxiety and Depression Scale (HADS), history of falls, and health resource utilisation.
Results: Patients with NV-AMD reported substantially worse vision-related functioning and overall well-being, including higher depression scores, than controls after adjusting for age, gender, and co-morbidities (adjusted mean scores: NEI-VFQ-25 overall 52.7 vs. 90.7, P<0.0001; EQ-5D 0.67 vs. 0.77, P=0.0273; HADS depression 6.8 vs. 4.0, P=0.0026). Significantly more patients reported a need for assistance with daily activities compared to controls (25.3% vs. 6.6%, P=0.003). Total annual healthcare utilisation costs were more than seven-fold higher for patients with AMD compared with controls (£3,823.89 vs. £517.05, respectively; P<0.0001)
Conclusions: NV-AMD patients show a significant decline in quality of life and increased need for daily living assistance compared to a control population without AMD. With the availability of effective new therapies there is a need for improved early access to treatment.
- burden of illness
- health resource utilisation
- neovascular age-related macular degeneration
- quality of life